New World Advisors LLC Has $374,000 Holdings in Elanco Animal Health Incorporated (NYSE:ELAN)

New World Advisors LLC grew its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 19.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 30,900 shares of the company’s stock after buying an additional 5,100 shares during the period. New World Advisors LLC’s holdings in Elanco Animal Health were worth $374,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. JPMorgan Chase & Co. lifted its position in shares of Elanco Animal Health by 76.6% in the third quarter. JPMorgan Chase & Co. now owns 10,057,656 shares of the company’s stock worth $147,747,000 after buying an additional 4,361,799 shares during the last quarter. State Street Corp lifted its position in shares of Elanco Animal Health by 2.6% in the third quarter. State Street Corp now owns 9,912,693 shares of the company’s stock worth $145,617,000 after buying an additional 255,084 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Elanco Animal Health by 0.8% in the third quarter. Geode Capital Management LLC now owns 7,868,675 shares of the company’s stock worth $115,623,000 after buying an additional 65,303 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Elanco Animal Health by 6.6% in the third quarter. The Manufacturers Life Insurance Company now owns 6,385,467 shares of the company’s stock worth $93,803,000 after buying an additional 394,921 shares during the last quarter. Finally, Wellington Management Group LLP increased its stake in shares of Elanco Animal Health by 19.2% in the third quarter. Wellington Management Group LLP now owns 4,007,805 shares of the company’s stock worth $58,875,000 after purchasing an additional 646,522 shares during the period. Institutional investors and hedge funds own 97.48% of the company’s stock.

Analyst Ratings Changes

ELAN has been the topic of a number of recent analyst reports. UBS Group initiated coverage on Elanco Animal Health in a research note on Monday, December 9th. They issued a “buy” rating and a $18.00 price objective on the stock. Barclays lifted their price objective on Elanco Animal Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, November 8th. Morgan Stanley dropped their price objective on Elanco Animal Health from $15.00 to $14.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 29th. Stifel Nicolaus dropped their price objective on Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Friday. Finally, Leerink Partnrs upgraded Elanco Animal Health to a “hold” rating in a research note on Monday, December 2nd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, Elanco Animal Health has an average rating of “Hold” and an average target price of $16.00.

Elanco Animal Health Trading Down 1.0 %

Shares of ELAN opened at $11.02 on Monday. Elanco Animal Health Incorporated has a 12-month low of $10.77 and a 12-month high of $18.80. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $5.45 billion, a price-to-earnings ratio of 27.54, a P/E/G ratio of 2.50 and a beta of 1.42. The stock’s 50-day moving average price is $11.80 and its 200 day moving average price is $13.10.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.